Summary by Futu AI
CLOVER BIO-B (STOCK CODE: 2197) VOLUNTARILY ANNOUNCES ITS DEVELOPMENT OF BIVALENT RSV CANDIDATE VACCINE SCB-1019 HAS RECEIVED POSITIVE PRELIMINARY DATA IN A PHASE I CLINICAL TRIAL. The trial, conducted in Australia, aims to assess the safety, responsiveness and immunogenicity of the vaccine in different age groups. After the first group of young adults (18-59 years old) received SCB-1019, a significant increase in geometric mean titration (GMTs) and geometric multiplicity elevations (GMFRs) of antibodies in RSV A and RSV B showed no significant change. These data show that SCB-1019 performed significantly or better in immunogenicity compared to other protein subunit RSV vaccines. In addition, no apparent safety or reactivity issues were observed in the first batch of the vaccine and it is planned to include the elderly group in Phase I clinical trials. Safety and immunogenicity results for the elderly population group are expected to be announced in the second half of 2024. Shareholders and potential investors should act with caution.